The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine hub. This initiative aims to integrate the strengths of three key cities in China’s biomedicine industry, leveraging their unique advantages to drive further growth and innovation.
Cities’ Profiles
- Taizhou is renowned for hosting the largest pharmaceutical industrial park with the most complete industrial chain in China. It is home to companies specializing in chemical medicine, biological products, diagnostic reagents, modern Chinese medicine, special formula food, and more.
- Lianyungang is a hub for leading domestic pharmaceutical companies, including Hengrui Pharmaceuticals, Hansoh Pharma, and Chia Tai Tianqing.
- Wuxi is globally competitive in drug design, clinical trials, and contract research organization (CRO) services. It is also home to major players like AstraZeneca and Wuxi Apptec.
Hub’s Performance
The Taizhou-Wuxi-Lianyungang hub can boast over 3,199 pharmaceutical companies, with 498 reaching a certain annual production threshold. As of the end of 2021, the industrial output value of clustered pharmaceutical enterprises reached RMB 304 billion (USD 42.24 billion), up 15% year-on-year. This accounts for about 9.02% of the total output value of the industry nationwide and nearly 50% of that of Jiangsu province. In 2021, the hub added 66 investment projects worth more than RMB 100 million (USD 13.89 million), totaling RMB 55.97 billion (USD 7.77 billion).-Fineline Info & Tech
